CTSO · Cytosorbents Corp - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | $2.73M | - | $2.82M | $2.80M | $2.52M | - | $4.11M | $3.39M | $3.22M | - |
| Gross Profit | $6.13M | - | $6.67M | $6.81M | $6.21M | - | $5.28M | $6.50M | $6.57M | - |
| R&D | $1.66M | - | - | - | - | - | $1.85M | $1.52M | $2.25M | - |
| SG&A | $8.15M | - | $8.61M | $9.17M | $8.43M | - | $7.00M | $7.58M | $8.57M | - |
| Total Operating Expenses | $9.17M | - | $9.53M | $10.43M | $10.09M | - | $9.68M | $9.92M | $11.50M | - |
| D&A | $289.0K | - | $300.0K | - | $368.5K | - | - | - | $397.3K | - |
| Operating Income | ($3.04M) | - | ($2.86M) | ($3.62M) | ($3.89M) | - | ($4.40M) | ($3.42M) | ($4.93M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | ($401.0K) | - | $0 | - | $0 | - | - | - |
| Net Income | ($5.13M) | - | ($3.17M) | $1.95M | ($1.48M) | - | ($2.33M) | ($4.14M) | ($6.36M) | - |
| EPS - Basic | ($0.08) | - | ($0.05) | $0.03 | ($0.02) | - | ($0.04) | ($0.08) | ($0.12) | - |
| EPS - Diluted | ($0.08) | - | ($0.05) | $0.03 | ($0.02) | - | ($0.04) | ($0.08) | ($0.12) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.81M | $6.25M | $7.54M | $10.20M | $11.59M | $3.28M | $5.69M | $8.46M | $8.61M | $14.13M |
| Accounts Receivable | $7.15M | $7.55M | $7.43M | $7.74M | $7.67M | $7.32M | $6.63M | $7.82M | $6.77M | $6.06M |
| Inventory | $4.48M | $5.28M | $4.00M | $3.71M | $3.02M | $2.73M | $3.25M | $4.32M | $3.74M | $3.68M |
| Accounts Payable | $3.13M | $2.87M | $3.04M | $3.39M | $3.33M | $3.34M | $2.34M | $3.05M | $2.40M | $3.80M |
| Current Assets | $17.76M | $20.63M | $21.31M | $22.99M | $25.41M | $21.60M | $16.60M | $21.96M | $19.99M | $25.70M |
| Total Assets | $40.56M | $44.18M | $45.75M | $47.99M | $50.78M | $47.37M | $47.80M | $53.43M | $47.07M | $53.26M |
| Current Liabilities | $16.30M | $9.71M | $10.11M | $9.84M | $9.74M | $9.82M | $8.43M | $10.34M | $13.42M | $14.55M |
| Long-term Debt | $10.31M | $16.67M | $14.57M | $14.38M | $14.19M | $14.00M | $13.81M | $13.67M | $1.93M | $2.54M |
| Total Liabilities | $38.37M | $38.28M | $36.73M | $36.40M | $36.24M | $36.26M | $34.80M | $36.69M | $28.14M | $29.99M |
| Stockholders' Equity | $2.19M | $5.90M | $9.02M | $11.59M | $14.54M | $11.11M | $13.00M | $16.74M | $18.93M | $23.28M |
| Retained Earnings | ($317.34M) | ($312.21M) | ($306.71M) | ($303.54M) | ($305.49M) | ($304.01M) | ($295.34M) | ($293.01M) | ($288.86M) | ($282.51M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($1.16M) | - | - | - | ($3.46M) | - | - | - | ($4.83M) | - |
| Investing Cash Flow | ($46.0K) | - | - | - | ($47.2K) | - | - | - | ($127.0K) | - |
| Financing Cash Flow | - | - | - | - | $6.83M | - | - | - | ($571.8K) | - |
| CapEx | $11.0K | - | - | - | $2.1K | - | - | - | $45.2K | - |
| Free Cash Flow | ($1.17M) | - | - | - | ($3.47M) | - | - | - | ($4.87M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.23 | - | - | - | 2.35 | - | - | - | 0.77 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -12.6% | - | -6.9% | 4.1% | -2.9% | - | -4.9% | -7.8% | -13.5% | - |
| Return on equity | -233.8% | - | -35.1% | 16.8% | -10.2% | - | -18.0% | -24.8% | -33.6% | - |
| Return on invested capital | -19.2% | - | -9.6% | - | -10.7% | - | -13.0% | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 1.09 | 2.13 | 2.11 | 2.34 | 2.61 | 2.20 | 1.97 | 2.12 | 1.49 | 1.77 |
| Quick ratio | 0.81 | 1.58 | 1.71 | 1.96 | 2.30 | 1.92 | 1.58 | 1.71 | 1.21 | 1.51 |
| Cash ratio | 0.30 | 0.64 | 0.75 | 1.04 | 1.19 | 0.33 | 0.67 | 0.82 | 0.64 | 0.97 |
| Leverage | ||||||||||
| Debt / Equity | 4.70 | 2.82 | 1.61 | 1.24 | 0.98 | 1.26 | 1.06 | 0.82 | 0.10 | 0.11 |
| Debt / Assets | 0.25 | 0.38 | 0.32 | 0.30 | 0.28 | 0.30 | 0.29 | 0.26 | 0.04 | 0.05 |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 18.49 | 7.48 | 5.07 | 4.14 | 3.49 | 4.27 | 3.68 | 3.19 | 2.49 | 2.29 |
| Liabilities / Assets | 0.95 | 0.87 | 0.80 | 0.76 | 0.71 | 0.77 | 0.73 | 0.69 | 0.60 | 0.56 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | 0.61 | - | 0.70 | 0.76 | 0.83 | - | 1.27 | 0.79 | 0.86 | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | 598d | - | 518d | 483d | 437d | - | 289d | 465d | 424d | - |
| Days payable outstanding | 418d | - | 393d | 442d | 482d | - | 208d | 328d | 272d | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | 42.7x | - | - | - | - | - | - |
| P / B | 16.2x | - | 6.5x | 7.4x | 4.2x | - | 6.3x | 2.3x | 2.7x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | -1.3% | - | 26.2% | 4.8% | -5.5% | - | -5.8% | 8.0% | 20.4% | - |
| Operating income growth (YoY) | 21.7% | - | 34.9% | -5.7% | 21.1% | - | 40.2% | 47.9% | 37.6% | - |
| Net income growth (YoY) | -246.9% | - | -35.8% | - | 76.7% | - | 74.6% | 32.7% | 13.2% | - |
| EPS growth (YoY) | -300.0% | - | -25.0% | - | 83.3% | - | 81.0% | 42.9% | 29.4% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 66.2% | - | - | - | 28.9% | - | - | - | -34.7% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -84.9% | -46.9% | -30.6% | -30.8% | -23.2% | -52.3% | -29.8% | -30.5% | -34.6% | -34.2% |
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing Cytosorbents Corp against the 5 most active filers in the same SIC group.